Biohaven Pharmaceutical Holding Company Ltd.
NYSE:BHVN
39.31 (USD) • At close February 4, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2022 Q1 | 2021 Q4 | 2021 Q3 | 2021 Q2 | 2021 Q1 | 2020 Q4 | 2020 Q3 | 2020 Q2 | 2020 Q1 | 2019 Q4 | 2019 Q3 | 2019 Q2 | 2019 Q1 | 2018 Q3 | 2018 Q2 | 2018 Q1 | 2017 Q4 | 2017 Q3 | 2017 Q2 | 2017 Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | -215.079 | 0 | 215.079 | 318.852 | 190.013 | 135.74 | 92.933 | 43.823 | 35.114 | 17.664 | 9.698 | 1.151 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0 | 0.977 | 0.941 | 0.948 | 0.857 | 0.8 | 0.764 | 35.741 | 0.377 | 0.456 | 26.342 | 35.949 | 25.514 | 17.339 | 12.862 | 9.968 | 4.244 | 3.058 | 0.424 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit
| 0 | -0.977 | -0.941 | -0.948 | -0.857 | -0.8 | -0.764 | -250.82 | -0.377 | 214.623 | 292.51 | 154.064 | 110.226 | 75.594 | 30.961 | 25.146 | 13.42 | 6.64 | 0.727 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.166 | 0 | 0.998 | 0.917 | 0.811 | 0.812 | 0.813 | 0.707 | 0.716 | 0.76 | 0.685 | 0.632 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 157.607 | 314.819 | 155.972 | 134.813 | 95.517 | 79.49 | 63.461 | 137.044 | 52.845 | 177.087 | 70.096 | 41.818 | 46.973 | 77.428 | 107.111 | 73.459 | 57.044 | 42.425 | 56.07 | 66.019 | 61.674 | 175.977 | 41.003 | 47.362 | 29.052 | 75.579 | 66.755 | 34.996 | 21.019 | 10.74 |
| General & Administrative Expenses
| 20.561 | 18.953 | 27.268 | 18.898 | 15.03 | 14.521 | 14.321 | 76.368 | 14.792 | 20.023 | 19.677 | 9.065 | 8.519 | 9.915 | 9.915 | 0 | 0 | 0 | 0 | 68.97 | 28.782 | 23.235 | 13.462 | 7.574 | 9.064 | 7.857 | 12.527 | 4.571 | 4.199 | 3.757 |
| Selling & Marketing Expenses
| 0 | 0 | -0.941 | -0.948 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 160.142 | 149.608 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 20.561 | 18.953 | 26.327 | 17.95 | 15.03 | 14.521 | 14.321 | 76.368 | 14.792 | 20.023 | 19.677 | 9.065 | 8.519 | 170.057 | 159.523 | 122.387 | 119.533 | 124.802 | 95.601 | 68.97 | 28.782 | 23.235 | 13.462 | 7.574 | 9.064 | 7.857 | 12.527 | 4.571 | 4.199 | 3.757 |
| Other Expenses
| 0 | 0 | 4.305 | 7.743 | 4.686 | 5.842 | 8.229 | -1.838 | 0 | -0.067 | -0.004 | 1.454 | -0.005 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Expenses
| 178.168 | 333.772 | 182.299 | 152.763 | 110.547 | 94.011 | 77.782 | 213.412 | 67.637 | 197.11 | 89.773 | 50.883 | 55.492 | 247.485 | 266.634 | 195.846 | 176.577 | 167.227 | 151.671 | 134.989 | 90.456 | 199.212 | 54.465 | 54.936 | 38.116 | 83.436 | 79.282 | 39.567 | 25.218 | 14.497 |
| Operating Income
| -178.168 | -333.772 | -183.24 | -153.711 | -110.547 | -94.011 | -77.782 | -213.412 | -67.637 | -197.11 | -89.773 | -50.883 | -55.492 | -171.891 | -235.673 | -170.7 | -163.157 | -160.587 | -150.944 | -134.989 | -90.456 | -199.212 | -54.465 | -54.936 | -38.116 | -83.436 | 79.282 | -39.567 | -25.218 | -14.497 |
| Operating Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.992 | 0 | -0.916 | -0.282 | -0.268 | -0.409 | -1.85 | -5.378 | -4.861 | -9.237 | -16.559 | -131.142 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 17.805 | 14.178 | 4.305 | 7.743 | 4.686 | 5.842 | 8.229 | -1.838 | 0 | -0.067 | -0.004 | 1.454 | -0.005 | -34.918 | -25.831 | -42.53 | -29.482 | -19.689 | -21.299 | -14.346 | -15.388 | -11.8 | -7.73 | -6.344 | -1.128 | -1.939 | 20.179 | -3.293 | -12.823 | -4.063 |
| Income Before Tax
| -160.363 | -319.594 | -178.935 | -145.968 | -105.861 | -88.169 | -69.553 | -215.25 | -67.637 | -197.177 | -89.777 | -49.429 | -55.497 | -206.809 | -261.504 | -213.23 | -192.639 | -180.276 | -172.243 | -149.335 | -105.844 | -211.012 | -62.195 | -61.28 | -39.244 | -85.375 | 99.461 | -42.86 | -38.041 | -18.56 |
| Income Before Tax Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.001 | 0 | -0.917 | -0.282 | -0.26 | -0.409 | -2.225 | -5.967 | -6.073 | -10.906 | -18.589 | -149.646 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| -0.059 | 0.177 | 0.569 | -1.212 | -3.287 | 2.177 | 0.939 | -14.143 | 1.216 | 6.11 | 7.255 | 2.457 | -1.132 | 4.35 | 3.824 | 4.886 | 3.989 | 0.658 | 0.694 | -0.071 | 0.323 | 0.058 | 0.109 | 0.161 | 0.025 | 0.087 | -0.647 | 0.055 | 0.399 | 0.193 |
| Net Income
| -160.304 | -319.771 | -179.504 | -144.756 | -102.574 | -90.346 | -70.492 | -201.107 | -68.853 | -203.287 | -97.032 | -51.886 | -54.365 | -210.619 | -264.968 | -217.736 | -195.189 | -180.934 | -172.937 | -149.264 | -106.167 | -211.07 | -62.304 | -61.441 | -39.269 | -85.462 | 100.108 | -42.915 | -38.44 | -18.753 |
| Net Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.935 | 0 | -0.945 | -0.304 | -0.273 | -0.401 | -2.266 | -6.046 | -6.201 | -11.05 | -18.657 | -150.249 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -1.7 | -3.64 | -2.2 | -1.81 | -1.5 | -1.32 | -1.03 | -3.3 | -1.75 | -5.67 | -2.71 | -1.45 | -1.52 | -3.23 | -4.27 | -4.49 | -3.27 | -3.08 | -3.07 | -0.003 | -2.04 | -4.67 | -1.41 | -1.53 | -1.01 | -2.32 | 2.753 | -1.19 | -1.48 | -1.43 |
| EPS Diluted
| -1.7 | -3.64 | -2.2 | -1.81 | -1.5 | -1.32 | -1.03 | -3.3 | -1.75 | -5.67 | -2.71 | -1.45 | -1.52 | -3.23 | -4.27 | -4.49 | -3.27 | -3.08 | -3.07 | -0.003 | -2.04 | -4.67 | -1.41 | -1.53 | -1.01 | -2.32 | 2.753 | -1.19 | -1.48 | -1.43 |
| EBITDA
| -176.174 | -331.818 | -181.794 | -151.817 | -109.009 | -92.18 | -76.133 | -214.906 | -67.26 | -196.695 | -89.523 | -50.198 | -55.266 | -56.022 | -56.022 | -215.296 | -163.157 | -160.587 | -150.944 | -134.989 | -90.456 | -199.212 | -54.465 | -54.936 | -38.116 | -83.436 | 79.282 | -39.567 | -25.218 | -14.497 |
| EBITDA Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.991 | 0 | -0.915 | -0.281 | -0.264 | -0.407 | -1.85 | -5.378 | -6.131 | -9.237 | -16.559 | -131.142 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |